Iressa (Head and Neck Cancer) Analysis and Forecasts to 2020


#28373

32pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Iressa (Head and Neck Cancer) Analysis and Forecasts to 2020 provides Iressa ERsales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the Japan (seven major markets)
  • Analysis and review of Iressa including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Iressa including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for Iressa in the US and EU5

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents 

 

1 Table of Contents 2
1.1 List of Tables 2
1.2 List of Figures 3


2 Introduction 4
2.1 Head and Neck Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 9
2.4 GlobalData Analysis and Forecasts Report Guidance 10


3 Head and Neck Cancer Disease: Market Characterization 11
3.1 Head and Neck Cancer Disease Market 11
3.2 Head and Neck Cancer Disease Market Forecasts and CAGR 11
3.3 Drivers for the Head and Neck Cancer Disease Market 12
3.3.1 High Incidence 12
3.3.2 Low Initial Diagnosis Rate 13
3.3.3 Emergence of Targeted Therapies and Vaccines 13


4 TumorNodeMetastases (TNM) Classification of Head and Neck Cancer 14


5 Iressa 22
5.1 Introduction 22
5.2 Mechanism of Action 22
5.3 Clinical Studies 22
5.4 Factors Affecting Sales of Iressa 23
5.4.1 Growing Head and Neck Cancer Market 23
5.4.2 Unmet Need 23
5.4.3 Superiority of Targeted Therapy 23
5.4.4 High Efficacy 23
5.5 Drug Evaluation 24
5.5.1 Drug Risk Benefit Score 24
5.5.2 Intensity of Competition 24
5.6 Sales Forecasts 25
5.6.1 Target Patient Pool of Iressa 25
5.6.2 Dosing 26
5.6.3 Market Penetration 26
5.6.4 Annual Cost of Therapy 26
5.6.5 Sales Projections of Iressa 27


6 Head and Neck Cancer Market: Appendix 28
6.1 Market Definitions 28
6.2 List of Abberiviations 28
6.3 Research Methodology 28
6.3.1 Coverage 28
6.3.2 Secondary Research 28
6.3.3 Forecasting 29
6.3.4 Number of Patients Approved to take the Drug 29
6.3.5 Net Penetration of Drug 29
6.3.6 Net Annual Dosing 30
6.3.7 Annual Cost of Therapy 31
6.3.8 Primary Research 31
6.3.9 Expert Panels 31
6.4 Contact Us 31
6.5 Disclaimer 31
6.6 Sources 32


Table 1: Head and Neck Cancer Incidences and Mortality, 2008-2030 4
Table 2: Head and Neck Cancer, Market Forecasts ($bn), Global, 20092020 11
Table 3: TNM Classification of the Oral cavity, Larynx, Oropharynx and Hypopharyngeal Cancers 14
Table 4: TNM Classification of the Nasopharyngeal Cancer 19
Table 5: Drug Risk Benefit Score 24
Table 6: Iressa, Head and Neck Cancer, The US, Sales Forecasts ($m), 20142020 27


Figure 1: Percentage Distribution of Top 20 Cancers, Based on Incidence Global, 2008 5
Figure 2: Percentage Distribution of Top 20 Cancers, Based on Mortality Global, 2008 6
Figure 3: Difference between Percentage Distribution of Incidence and Mortality of Top 20 Cancers , 2008 7
Figure 4: Percentage Distribution of Various Cancer Types in Head and Neck Considering US, EU-5 and Japan Incidence, 2008 8
Figure 5: Percentage Distribution of Various Cancer Types in Head and Neck Considering Global Incidence, 2008 8
Figure 6: Per Capita Cigarette Consumption Curve, the US, 1976-2006 9
Figure 7: Head and Neck Cancer, Market Forecasts ($bn), Global, 20092020 11
Figure 8: Oncology Incidence (in billion), Global, 2008-2030 12
Figure 9: Head and Neck Cancer Incidence (in billion), Global, 2008-2030 12
Figure 10: Broad Classification of Head and Neck Cancer 14
Figure 11: Detailed TNM Classification of Oral Cavity Cancer 15
Figure 12: Detailed TNM Classification of Laryngeal Cancer 16
Figure 13: Detailed TNM Classification of Oropharyngeal Cancer 17
Figure 14: Detailed TNM Classification of Hypopharyngeal Cancer 18
Figure 15: Detailed TNM Classification of Nasopharyngeal Cancer 20
Figure 16: Classification of Head and Neck Cancer 21
Figure 17: Drug Model Diagram of Iressa 25
Figure 18: Iressa, Head and Neck Cancer, The US, Sales Forecasts ($m), 20142020 27
Figure 19: Drug Model Diagram 30
Figure 20: Patients Approved for The Drug 30